Merck Center for Catalysis at Princeton University, Princeton, New Jersey 08544, United States.
Pharmaceutical Candidate Optimization, Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08542, United States.
J Am Chem Soc. 2020 Dec 23;142(51):21260-21266. doi: 10.1021/jacs.0c09926. Epub 2020 Dec 8.
Bioconjugation technologies have revolutionized the practice of biology and medicine by allowing access to novel biomolecular scaffolds. New methods for residue-selective bioconjugation are highly sought to expand the toolbox for a variety of bioconjugation applications. Herein we report a site-selective methionine bioconjugation protocol that uses photoexcited lumiflavin to generate open-shell intermediates. This reduction-potential-gated strategy enables access to residues unavailable with traditional nucleophilicity-based conjugation methods. To demonstrate the versatility and robustness of this new protocol, we have modified various proteins and further utilized this functional handle to append diverse biological payloads.
生物共轭技术通过提供新型生物分子支架,彻底改变了生物学和医学的实践。人们迫切需要新的残基选择性生物共轭方法,以扩展各种生物共轭应用的工具包。在此,我们报告了一种使用光激发黄素生成开壳中间体的甲硫氨酸选择性生物共轭方案。这种还原电位门控策略可以获得传统亲核性共轭方法无法获得的残基。为了证明这个新方案的多功能性和稳健性,我们已经修饰了各种蛋白质,并进一步利用这个功能接头来附加各种生物有效载荷。